Table 4 Evaluation of toxicity per patient

From: A phase II study of S-1 monotherapy administered for 2 weeks of a 3-week cycle in advanced gastric cancer patients with poor performance status

 

Number of patients ( N =52)

  
 

G1

G2

G3

G4

Toxicity of all gradesa (%)

Toxicity of grade 3–4 (%)

Haematologic toxicity

 Anaemia

8

23

2

1

65

6

 Leukopaenia

6

9

3

—

35

6

 Neutropaenia

7

7

5

—

37

10

 Thrombocytopaenia

4

2

—

2

15

4

Non-haematologic toxicity

 Diarrhoea

10

3

7

—

39

14

 Nausea

17

10

1

—

54

2

 Vomiting

8

7

1

—

32

2

 Mucositis

15

4

—

—

37

—

 Anorexia

15

20

7

—

81

14

 Fatigue

17

13

5

—

67

10

 Weight loss

4

3

—

—

14

—

 Dyspepsia

15

5

1

—

40

2

 Skin rash

8

1

—

—

17

—

 Itching sensation

12

2

—

—

27

—

 Skin pigmentation

13

1

—

—

27

—

 Hand – foot syndrome

2

2

1

—

10

2

 Abdominal pain

12

2

—

—

27

—

 Elevated creatinine

8

—

—

—

15

—

 Elevated AST/ALT

10

4

—

—

27

—

 Elevated ALP

12

1

2

1

29

6

 Hyperbilirubinaemia

8

2

1

1

23

4

  1. ALP=alkaline phosphatase; ALT=alanine aminotransferase; AST=aspartate aminotransferase; G=Grade.
  2. aGrading was according to the NCI-Common Toxicity Criteria (Version 2.0).
Back to article page